Navigation Links
Newfound roadblock to interferon effectiveness against malignant melanoma

Researchers have uncovered a significant contributing factor to interferon resistance of malignant melanoma cells. The finding represents a step forward in understanding the molecular events that govern the growth of this type of cancer and the changes in gene expression and cellular signaling that underlie resistance to established therapies.

Malignant melanoma is the deadliest form of skin cancer, and if not treated successfully, it can spread to affect the liver, lungs, or brain. Chemotherapy fights the disease with limited efficiency, and the use of interferon has become the most established immunotherapy for advanced-stage melanoma. However, melanoma tumors often develop a resistance to the drug, posing one of the major obstacles in the clinical treatment of this cancer.

Now Professor Manfred Schartl and Dr. Claudia Wellbrock, scientists at the University of W�rzburg, believe they have an explanation for how this interferon resistance is acquired. They have found that when a gene called STAT5 is too active in melanoma cells, it can counteract the anti-cancer effect of interferon. Interferon normally impedes the growth of cancer cells, whereas STAT5 is thought to act to promote cellular growth.

The new work, published by Professor Schartl and his colleagues in Current Biology, shows that interferon actually activates STAT5 in melanoma cells but that under normal conditions, this does not interfere with the inhibitory potential of the drug. However, when cancer cells posses too much STAT5 activity to begin with, the further activation of STAT5 function by interferon induces a mechanism that blocks the ability of the drug to effectively inhibit growth.

Confirming this initial finding, the researchers found that when they inhibited STAT5 in interferon-resistant melanoma cells, they were able to restore the effectiveness of interferon. This demonstrates the relevance of STAT5 and its contribution to the behavior of melanoma cells in th
'"/>

Source:Cell Press


Page: 1 2

Related biology news :

1. Hepatitis C responds best to combo of ribavirin and interferon, study concludes
2. Greasing interferons gears may pave way to greater therapeutic benefits, fewer side effects
3. Combination therapy boosts effectiveness of telomere-directed cancer cell death
4. Man-made wetlands effectiveness similar to natural marsh
5. UCLA study assesses cost-effectiveness of Hepatitis B drugs
6. Structures of marine toxins provide insight into their effectiveness as cancer drugs
7. Test reveals effectiveness of potential Huntingtons disease drugs
8. Nitric oxide: Key to cardiovascular and pulmonary function and drug effectiveness
9. Enzyme, lost in most mammals, is shown to protect against UV-induced skin cancer
10. Bound for destruction: Ubiquitination protects against improper Notch signaling
11. Female sex hormones play a vital role in defense against sexually transmitted diseases
Post Your Comments:
(Date:11/21/2014)... Nov. 19, 2014  Earlier this year Donald ... College, and one of the most prolific inventors in ... are transmitted from Smartphones to third party agencies. Spector ... has one of the earliest known patents in this ... in the military, child care, elder care and hospital ...
(Date:11/21/2014)... Nov. 20, 2014   Atmel® Corporation (NASDAQ: ... (MCU) and touch technology solutions, today launched the industry,s ... with the widest V cc range from 1.7V ... and faster I 2 C bus communication speeds, and ... memory making them ideal for consumer, industrial, computer, and ...
(Date:11/18/2014)... The Parenteral Drug Association (PDA) today confirmed that seven officials ... least seven more will participate in the upcoming 2014 PDA ... Washington D.C. , Dec. 2-4. ... the regulatory agencies in the United States ... to help advance the use of metrics in the regulatory ...
Breaking Biology News(10 mins):Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 2Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 3Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 4Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 2Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 3Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 4FDA's Janet Woodcock, EMA's Emer Cooke Headline PDA Quality Metrics Conference 2
... bacteria exist as aggressive pathogens, causing diseases ranging from ... syndrome, others play a less malevolent role and some ... study, Cheryl Nickerson and her group at ASU,s Biodesign ... Van de Wiele and lead author Rosemarie De Weirdt ...
... participation in scientific research has deep roots in the ... has taken off spectacularly from launch pads across the ... communications technology and a sea change in a scientific ... Citizen science, crowd-sourced science, DIY research, volunteer monitoring, ...
... A study comparing whether endothelial colony-forming cells (ECFCs) derived from ... are more proliferative and better for forming new blood vessels ... vasculogenic., The study, carried out by researchers at the Indiana ... Cell Medicine [2(3)] and is freely available on-line ...
Cached Biology News:Beneficial bacteria may help ward off infection 2Beneficial bacteria may help ward off infection 3Beneficial bacteria may help ward off infection 4Beneficial bacteria may help ward off infection 5Inaugural cross-disciplinary Public Participation in Scientific Research conference 2Blood vessel forming potential of stem cells from human placenta and umbilical cord blood 2
(Date:11/23/2014)... 2014 Apiscent Labs, a privately ... chemical ingredients to the global pharmaceutical and flavor ... new website, Apiscent.com. , The Apiscent.com homepage welcomes ... design, easy navigation, rotating images and content focused ... out. , The company’s work in ...
(Date:11/22/2014)... VA (PRWEB) November 21, 2014 During ... who understood the need to surround himself with great ... CEO and entrepreneur, his friends often marveled at his ... he lived his life and -- even with his ... for the Alzheimer’s disease that would ultimately take his ...
(Date:11/22/2014)... November 21, 2014 CannLabs, Inc. ... based analytics and scientific testing methodologies relating to cannabis, ... a $750,000 line of credit from an existing stockholder ... to have secured this commitment from one of our ... of CannLabs. “This capital will help accelerate our planned ...
(Date:11/22/2014)... 2014 On November 17th Chicago start-up ... Emerging Medical Technologies Summit in San Francisco to take ... regarded among Silicon Valley investors and technology elites as ... win also positions Briteseed to move on to ... 2015 and compete with other elite innovation finalists for ...
Breaking Biology Technology:Sherry Sharp, Wife of CarMax Founder, Richard Sharp, Accepts Seat on Board of Cure Alzheimer’s Fund 2Sherry Sharp, Wife of CarMax Founder, Richard Sharp, Accepts Seat on Board of Cure Alzheimer’s Fund 3CannLabs Secures $750,000 Line Of Credit 2Insight Product Development Accelerator Member Wins MedTech Innovator Award Competition 2Insight Product Development Accelerator Member Wins MedTech Innovator Award Competition 3
... and OSLO, March 4 Pharmexa A/S and Affitech ... agreement to merge,the two companies by means of a ... Norwegian company, Affitech AS. The purpose of the merger ... vaccine business,into a company focused on the research and ...
... milestones, - Strong R&D investments, especially in EHT Dx21 and EHT ... Recruitment of 311 samples achieved for EHT Dx21, - ... Expansion of the strategic collaboration with Allergan and extension, ... of a new Management Board, - New positioning of Genomic Services ...
... highlights the importance and challenges of ... America. To move beyond the current crisis, we ... knowledge-intensive jobs, invest in "green" science and engineering ... based industries and workers. , Nanotechnologywhich some scientists ...
Cached Biology Technology:Pharmexa and Affitech to Combine Operations to Create a New Antibody Therapeutics Company 2Pharmexa and Affitech to Combine Operations to Create a New Antibody Therapeutics Company 3ExonHit Therapeutics Invested Strongly in 2008 for Pivotal 2009 Results 2ExonHit Therapeutics Invested Strongly in 2008 for Pivotal 2009 Results 3ExonHit Therapeutics Invested Strongly in 2008 for Pivotal 2009 Results 4ExonHit Therapeutics Invested Strongly in 2008 for Pivotal 2009 Results 5ExonHit Therapeutics Invested Strongly in 2008 for Pivotal 2009 Results 6ExonHit Therapeutics Invested Strongly in 2008 for Pivotal 2009 Results 7ExonHit Therapeutics Invested Strongly in 2008 for Pivotal 2009 Results 8ExonHit Therapeutics Invested Strongly in 2008 for Pivotal 2009 Results 9ExonHit Therapeutics Invested Strongly in 2008 for Pivotal 2009 Results 10ExonHit Therapeutics Invested Strongly in 2008 for Pivotal 2009 Results 11Nanotechnology: Will it drive a new innovation economy for the US? 2Nanotechnology: Will it drive a new innovation economy for the US? 3
IHC detection kit for PCNA in cells and tissues...
... Immunogen: Synthetic peptide derived from the ... protein. Specificity: Reacts with the ... Reactivity: Human Mouse (positive controls: WNT1-transfected ... lysates and mouse Mouse-1 cell lysates). ...
The pYES2 vector is designed for native expression of your protein of interest in S. cerevisiae. It contains the URA3 gene for selection in yeast and 2 origin for high-copy maintenance....
... cAMP - [125I] Direct SPA ... SPA.Includes lysis reagents that eliminate lengthy ... cAMP measurement (optional use).Range: 1.32-84.28 ng/ml ... pmol/ml).Overnight protocol.Store at 2-8 C. Category: ...
Biology Products: